Introduction {#Sec1}
============

Platelet-rich fibrin (PRF) is becoming an attractive and widely-used approach in regenerative dentistry. PRF is a platelet-rich plasma that undergoes natural coagulation after being separated from the red thrombus by centrifugation \[[@CR1]\]. The evolution of PRF started with the introduction of L-PRF based on a high-speed protocol (\~ 700 g for 12 min) \[[@CR1]\]. Later on, A-PRF (\~ 200 g for 8 min) and injectable PRF (\~ 60 g for 3 min) with lower g-forces and centrifugation times were introduced with the overall aim to increase the number of platelets and leucocytes \[[@CR2]\]. For this aim, the use of centrifuges with swing-out rotors has also been recommended \[[@CR2]\]. Obviously PRF is an umbrella term that comprises various preparations and protocols, therefore a standardization of relative centrifugal forces (RCF) \[[@CR3]\] has been suggested. Nonetheless, most of the clinical data derive from the classical L-PRF protocol \[[@CR1]\].Fig. 1PRISMA Flow Diagram

Recent systematic reviews dealt with the clinical application of PRF in periodontal defects, periodontal plastic surgery \[[@CR4]\], sinus floor elevation, alveolar ridge preservation, or implant therapy \[[@CR5]\]. For example, PRF preserves the alveolar ridge after tooth extraction \[[@CR6]\], enhances osseointegration in the early phase \[[@CR7], [@CR8]\] and can increase the width of keratinized mucosa around implants \[[@CR9]\]. Even though emerging evidence indicates that local application of PRF can support the outcomes of the above-mentioned clinical indications, the underlying cellular mechanisms remain unclear. Based on the assumption that PRF supports the conserved cellular mechanisms of wound healing and bone regeneration, it can, therefore, be assumed that PRF drives the cellular responses also under in vitro conditions.

In vitro bioassays can confirm the impact of PRF on standard cellular responses such as proliferation, migration, and differentiation, all of which may predict a possible clinical efficacy. However, care should be taken when interpreting the observations, as the early hematoma that usually forms in defect sites is not represented in the in vitro assays \[[@CR10]\]. Readers of this review should also be aware that some of the observations reported for PRF have already been shown for plasma-free leucocyte-depleted activated platelets \[[@CR11]--[@CR13]\] based on the compelling in vitro evidence gained from platelet-rich plasma \[[@CR14], [@CR15]\].

The cellular responses to PRF were summarized in a systematic review integrating seven in vitro studies \[[@CR16]\]. However, given the increasing number of in vitro studies, not limited to dentistry, a revised view on today\'s in vitro research on PRF seems justified. This systematic review aims to provide an update of the existing research on how PRF affects basic physiological processes in vitro.

Material and methods {#Sec2}
====================

Protocol development and eligibility criteria {#Sec3}
---------------------------------------------

A protocol including all aspects of a systematic review methodology was developed prior to starting the review. This included definition of the focused question, a defined search strategy, study inclusion criteria, determination of outcome measures, screening methods, data extraction, and analysis and data synthesis.

Defining the focused question {#Sec4}
-----------------------------

The following focused question was defined: "what is the effect of PRF on cell behavior in in vitro studies?"

Search strategy {#Sec5}
---------------

An electronic search using MEDLINE database was performed. Articles published up to June 30, 2018 were considered. No language or time restrictions were applied in the search. However, only studies written in English were included for selection.

Search terms {#Sec6}
------------

The electronic search strategy included terms related to the intervention and used the following combination of key words and MeSH terms: leukocyte platelet-rich fibrin" OR "pure platelet-rich fibrin" OR "LPRF" OR "L-PRF" OR "advanced platelet-rich fibrin" OR "APRF" OR "A-PRF" OR "L-PRF Gel" OR "leukocytes" OR "platelets" OR "blood platelets" OR "platelet" AND "in vitro techniques" OR "cytokines" OR "intercellular signaling peptides and proteins" OR "intercellular" OR intercellular signaling peptides and proteins" OR "growth factors" OR "transforming growth factor beta" OR "bone marrow" OR "stem cells" OR "macrophages" OR "osteoclasts" OR "inflammation" OR "Cell Physiological Phenomena" OR "Cell Plasticity" OR "cell differentiation" OR "osseointegration" OR "Dental Implants."

Criteria for study selection and inclusion {#Sec7}
------------------------------------------

Only in vitro studies evaluating the effect of PRF were considered.

Exclusion criteria {#Sec8}
------------------

In vitro studies using other kinds of platelet concentrates such as PRGF or PRP or any other platelet concentrate that required the addition of anticoagulant. Pre-clinical and in vitro studies that did not use human blood.

Screening and selection of studies {#Sec9}
----------------------------------

Publication records and titles identified by the electronic search were independently screened by two reviewers (JN and ZK) based on the inclusion criteria. Discrepancies were solved by discussion among authors (RG and FJS). Cohen's Kappa-coefficient was used as a measure of agreement between the readers. Thereafter, full texts of the selected abstracts were obtained. The two reviewers independently performed the screening process, i.e., from the MeSH term search up to the full-text examination. Then, articles that met the inclusion criteria were processed for data extraction.

Data extraction and analysis {#Sec10}
----------------------------

The inclusion criteria were applied for data extraction. The studies were classified according to study design and type of methods applied. Then, outcomes were compiled in tables. All extracted data were double-checked, and any questions that came up during the screening and the data extraction were discussed within the authors to aim for consensus.

Results {#Sec11}
=======

Selection of studies {#Sec12}
--------------------

In the original search 1746 potential references were identified in Medline which 59 were eligible after title and abstract screening (inter-reviewer agreement *κ* = 0.952). Of the 59 full-text articles, 22 did not meet the inclusion criteria and were excluded (Fig. [1](#Fig1){ref-type="fig"}) obtaining 37 studies for data extraction (Table [1](#Tab1){ref-type="table"}). During the submission-process of the present review, 16 new studies meeting the inclusion criteria were published and therefore included for data extraction (Table [2](#Tab2){ref-type="table"}).Table 1Included studiesStudy (year)Cell typePRF preparationMethodMain outcome induced by PRFBeitzel et al. (2014) \[[@CR17]\]Human mesenchymal stem cells (MSCs)3000 rpm10 minHardware:NRCell viability by live and dead stainingCell adhesion assay to the PRF-MatrixCell proliferation by incorporation of 3H-thymidineCell viability maintainedIncreased cell adhesionNo effect in cell proliferation on collagen membranesBurnouf et al. (2012) \[[@CR18]\]Human embryonic kidney fibroblasts (HEK293), human osteoblastic cell line (MG-63), SIRC, NIH/3T3, periodontal ligament cells (PDL), gingival fibroblasts (GF)700 g12 minHardware:^a^Cell proliferation by an automated cell counterIncreased proliferation of all cells except for NIH/3T3 after 7 days of stimulationChang et al. (2010) \[[@CR19]\]Osteoblast cell line U2OS3000 rpm12 minHardware:^a^Cell proliferation by MTT assayWestern blot for ERK phosphorylation, RANKL and OPG expressionIncreased proliferation after 1, 3 and 5 daysIncreased ERK phosphorylation during 5 days and OPG expression during 3 daysChang et al. (2011) \[[@CR20]\]Periodontal ligament fibroblasts (PDLFs)3000 rpm12 minHardware:^a^Western blot for p-ERK and OPG ALP activityIncreased ERK phosphorylation and OPG protein expression up to 5 daysEnhanced ALP activity up to 5 daysClipet et al. (2012) \[[@CR21]\]SaOS2 (osteoblasts), MRC5 (fibroblasts) KB (epithelial cells)400 g12 minHardware: NRCell proliferation by SRB assayCytotoxic assay by SRB assayCell cycle analysis by flow cytometry testsGene expression of cbfa1, Col1, OC and OP by RT-PCRIncreased proliferation of SaOS2, MRC5 and KBEnhanced G2M phase in SAOS2 and MRC5 lineagesUp-regulation of OP and OC on SAOS2Dereli et al. (2018) \[[@CR22]\]Limbal epithelial cellsPRF gel: 1000 rpm/5 minPRF: 2700 rpm/12 minHardware:^b^Cell viability by live and dead stainingCell viability maintainedDohle et al. (2018) \[[@CR23]\]Human outgrowth endothelial cells (OECs) primary osteoblasts (pOBs)700 rpm3 minHardware:^c^Co-culture of OECs with pOBsAngiogenic activation by immunofluorescent stainingELISA for VEGF, PDGF-BB, E-selectin and ICAM-1Gene expression of VEGFA, ICAM1, PDGF-BB, E-selectin. BMP2 and ALP by RT-PCRIncreased VEGF concentration on pOBs at 7 daysIncreased of PDGF and E-Sel levels in OECs and pOBs co-cultures at the mRNA level and protein level at 24 and 72 hIncreased expression of ICAM1 and ALP at 24 h in OECs and pOBs co-culturesUpregulation of VEGF expression in PRF/co-culture at 1 and 7 daysIncreased BMP2 expression in PRF co-cultures cultivated at 1 and 7 daysEhrenfest et al. (2009) \[[@CR24]\]Osteoblasts, fibroblasts, preadipocytes, prekeratinocytes400 g12 minHardware:^a^Proliferation assayCytotoxicity by MTT assayOsteoblast differentiation by Von Kossa and ALP stainingIncreased proliferation of fibroblasts and osteoblasts at 3, 7, 14 and 21 days in a dose-dependent manner on osteoblastsAbsence of cytotoxicity in all cellsIncreased ALP activity after 3 days and up to 28 days and increased osteoblasts differentiation after 7 days and up to 28 daysEhrenfest et al. (2010) \[[@CR25]\]Human bone mesenchymal stem cells (BMSC)400 g12 minHardware:^a^Proliferation and cytotoxicity by MTT assayOsteoblastic differentiation by ALP activity and quantification of the mineralization nodulesIncreased proliferation in standard and osteogenic conditions in a dose-dependent mannerAbsence of cytotoxicity on BMSC in standard or osteogenic conditionsIncreased ALP activity in a dose-dependent manner in standard and osteogenic conditionsGassling et al. (2013) \[[@CR26]\]Human osteoblasts400 g12 minHardware: NRCell viability by live and dead stainingBiocompatibility and cell proliferation by lactate dehydrogenase, BrdDU, MTT and WST-1Alkaline phosphatase activity by ELISACell viability maintainedIncreased ALP activityGassling et al. (2010) \[[@CR27]\]Human periosteal cells400 g12 min2700 rpmHardware:^d^Cell viability by live and dead stainingBiocompatibility test by LDH test and MTT assayCell Proliferation by BrdUCells seeded on PRF membranes maintained their viabilityPRF membranes were biocompatibleNo effect on proliferationHe et al. (2009)\[[@CR28]\]Rat calvaria osteoblasts400 g10 minHardware: NRCell ProliferationALP activityMineralization assay by alizarin red stainingIncreased proliferation at 5 days and enhanced mineralization at 14 daysNo effect on ALP activityHe et al. (2016) \[[@CR29]\]Human dental pulp cell (hDPC)400 g10 minHardware: NRProliferation assay by CCK-8Gene expression of ALP and DSPP by RT-PCRIncreased proliferation after 5 and 7 daysUp-regulation of ALP and DSPP expressionHong et al. (2018) \[[@CR30]\]Human Stem Cells of the Apical Papilla (SCAPs)400 g10 minHardware: NRCell proliferation assayCell migration assayOsteogenic differentiation by alizarin red stainingGene expression of ALP, BSP, DMP1, and DSPP by RT-PCRIncreased proliferation at 1, 3, 5 and 7 daysEnhanced migration at 12 and 24 hIncreased mineralization at 7 and 14 daysDown-regulation of ALP, BSP, DMP1 expression but not DSPP after 7 daysUp-regulation of ALP, BSP, DMP1 and DSPP expression after 14 daysHuang et al. (2010) \[[@CR31]\]Dental pulp cells (DPCs)3000 rpm10 minHardware:^a^Cell proliferation by MTT assayWestern blot for OPGALP activity assayIncreased DPC proliferation at 1, 3 and 5 daysUp-regulation of OPG expression in a time-dependent mannerIncreased ALP activityKang et al. (2011) \[[@CR32]\]Human alveolar bone marrow stem cells (hABMSCs)400 g/10 min + 230 g/10 minHardware: NRCell proliferation by BrdU assayCell migration by wound-healing assayMineralization by alizarin red stainingIncreased proliferationReduced migration at 1 and 2 daysEnhanced mineralizationKhurana et al. (2017) \[[@CR33]\]Dental pulp stem cells (DPSCs) periodontal ligament stem cells (PDLSCs)3000 rpm10 minHardware: NRCell viability by trypan blueAbsence of cytotoxicity at 7 daysKim et al. (2017) \[[@CR34]\]Human derived osteoblasts400 g10 minHardware:^e^Cell proliferation by MTT assayOsteoblast differentiation by Sulforhodamine B assayALP activityIncreased proliferation at 1, 2 and 3 daysEnhanced osteoblast differentiationIncreased ALP activity at 2 and 3 daysKim et al. (2017) \[[@CR34]\]Human dental pulp cells (HDPCs)400 g10 minHardware: NRCell viability by MTT assayELISA for IL-1β, IL-6, and IL-8Western blot for VCAM1 and ICAM1 and odontoblastic differentiation markers DSP and DMP1ALP ActivityMineralization by alizarin red stainingAbsence of cytotoxicityReduced LPS-induced pro-inflammatory cytokines IL-1b, IL-6, and IL-8 at 1 and 3 days and LPS-induced adhesion molecules VCAM1 and ICAM1 at 1 dayEnhanced LPS-induced up-regulation of odontoblastic differentiation markers DSP and DMP1 at 3 daysIncreased ALP activity and mineralization at day 7 in LPS treated cellsKobayashi et al. (2015) \[[@CR35]\]Human umbilical vein endothelial cells (HUVECs)600 g/2 min + 500 g/4 min + 800 g/3 minHardware:^f^Scratch assayWestern blot for VEGFR2New blood vessel formation by CAM assayIncreased migrationEnhanced phosphorylation of VEGFR2 in a dose-dependent mannerIncreased number of blood capillariesFujioka-Kobayashi et al. (2017)\[[@CR36]\]Human gingival fibroblastsL-PRF: 708 g/12 minA-PRF: 200 g/14 minA-PRF+: 200 g/8 minHardware:^c^Cell viability by live-dead stainingCell migration assayCell proliferation by MTS assayGene expression of TGFβ, PDGF, and COL1a2 by RT-PCRCell viability maintainedIncreased migrationIncreased proliferation at 3 and 5 daysUp-regulation of PDGF and COL1a2 expression and TGFβ, PDGF and COL1a2 at day 7A-PRF+ produced the highest expression of TGFβ and COL1a2Liang et al. (2018) \[[@CR37]\]Nanofat-derived stem cells (NFSCs)2700 rpm12 minHardware: NRCell proliferation by CCK-8Gene expression of VEGF, bFGF, PDGF and TGFβ by RT-PCRProtein levels by Western blotIncreased proliferationIncreased expression and protein levels of VEGF, bFGF, PDGF and TGFβEnhanced osteogenic, adipogenic and chondrogenic differentiationMiron et al. (2017) \[[@CR38]\]Human gingival fibroblasts (HGF)I-PRF:700 rpm60 g3 minHardware:^c^Cell viability by live and dead assayCell migration by Boyden chamberCell proliferation by MTS assayGene expression of TGFβ, PDGF and COL1a2 by RT-PCRAbsence of cytotoxicityIncreased cell migrationIncreased proliferation after 5 daysUpregulation of COL1a2 and PDGF expression after 3 days, and TGFβ and COL1a2 after 7 daysMoradian et al. (2017) \[[@CR39]\]Human bone marrow mesenchymal stem cells (BMMSCs)400 g10 minHardware: NRCell proliferation by MTT assayIncreased proliferation at 7 daysSchär et al. (2015) \[[@CR40]\]Human bone marrow-derived MSC and HUVEC400 g12 minHardware:^b^Cell migration assay by Boyden chambersIncreased migration of MSC and HUVEC cells at 7 days and at 8 h, respectivelyPark et al. (2018) \[[@CR41]\]Human umbilical vein endothelial cell (HUVEC)400 g12 minHardware:^a^Cell proliferation by MTT assayCytotoxicity assay by adenylate kinase (AK) release from dead cellsCell migration by Boyden chamber assayCell attachment by Green Nucleic Stain-KitIncreased proliferation, migration and attachment of cells by coating porcine-matrices with PRFIncreased cytotoxicity at day 1Passaretti et al. (2014) \[[@CR42]\]HUVEC, skin fibroblasts400 g12 minHardware:^a^Cell proliferation by Bürker chamber counting and automated cell counterIncreased cell proliferation at 24 hSaeed et al. (2017) \[[@CR43]\]Dental pulp stem cells (DPSCs)2700 rpm12 min + 1800 rpm/5 minHardware: NRCell proliferation by MTS assayOsteogenic differentiation by alizarin red assayReduced cell viability at 1 and 3 days by most PRF concentrationsEnhanced osteogenic differentiation at 7 daysVahabi et al. (2015) \[[@CR44]\]Human gingival fibroblasts cell line (HGF)400 g12 minHardware: NRViability and proliferation by MTT assayCell viability maintained during the first 24 h, at 48 and 72 h cell viability is reducedIncreased proliferation only the first 24 hWang et al. (2018) \[[@CR45]\]Human primary osteoblastsI-PRF:700 rpm60 g3 minHardware:^c^Cell viability by live and dead stainingCell migration by polyethylene terephthalate cell culture insertsCell adhesion assay by staining cells with 4′,6-diamidino-2-phenylindoleCell proliferation by CCK-8ALP activity assayMineralization by alizarin red stainingGene expression of COL1A, Runx2, ALP, OCN by RT-PCRImmunofluorescence staining for OC expressionCell viability maintainedIncreased migration at 1 dayNo effect on cell adhesionIncreased proliferation at 3 and 5 daysEnhanced ALP activity and mineralized nodule formationUp-regulation of ALP expression at 3 days and OCN, Runx2 and COL1A at 14 daysIncreased staining intensity of OCNWang et al. (2017) \[[@CR46]\]Human gingival fibroblasts700 rpm60 g3 minHardware:^c^Cell viability by live-dead staining assayCell migration assay by polyethylene terephthalate cell culture insertsCell adhesion assayCell proliferation by CCK-8Gene expression of PDGF, TGFβ and COL1a1 and FN1Collagen Type I Staining ImmunostainingCell viability maintained irrespective of the titanium surfaceIncreased migration in tissue culture plates and titanium surfacesNo effect on cell adhesionIncreased cell proliferation after 3 and 5 daysUpregulation of PDGF, TGF-b, COL1 and FN1 expression levels on all surfacesIncreased fluorescence intensity of collagen type 1 on all surfaces.Wei et al. (2017) \[[@CR47]\]Nanofat-derived Stem Cells (NFSCs)2700 rpm12 minHardware: NRProliferation assay by CCK-8Gene expression of adipogenic differentiation markers PPARγ2, C/EBPα, and ADD1 by RT-PCRIncreased proliferation after 3 daysEnhanced adipogenic differentiation at 14 days in a dose dependent-mannerUp-regulation of PPARγ2, C/EBPα, and ADD1 expressionWirohadidjojo et al. (2016)\[[@CR48]\]Ultraviolet-A (UVA)-irradiated human dermal fibroblasts (HDFs)400 g12 minHardware: NRProliferation assay by MTT assayCollagen deposition assayCell migration rate assayIncreased proliferation, migration and collagen deposition in UVA-irradiated HDFsWoo et al. (2016) \[[@CR49]\]Human dental pulp cells (HDPCs)400 g10 minHardware: NRCell viability by MTT and MTA assayALP activity assayALP stainingAlizarin red staining for mineralization formationWestern Blot for DSP,DMP1, BMP 2/4, phospho-smad1/5/8Cell viability maintained at 48 hIncreased protein levels of DSP and DMP1 and enhanced ALP activity.Increased mineralizationActivation of BMP 2/4 signaling and phosphorylation of SMAD1/5/8Wu et al. (2012) \[[@CR50]\]Human osteoblast cell line (U2OS)3000 rpm12 minHardware:^c^Cell attachment assay by WST-1 assayCell proliferation assayWestern blot analysis for p-Akt, HSP 47 and LOXIncreased cell attachment the first 3 hIncreased proliferation at 1, 3 and 5 days.Enhanced Akt phosphorylation, HSP 47 expression, and LOX expression in U2OS cellsXu et al. (2016) \[[@CR51]\]Human breast adipose-derived stem cells (HBASCs)2700 rpm12 minHardware: NRAttachment of HBASCs on scaffolds in the presence of PRF, Rg1 or both by fluorescence imagingIncreased proliferation and attachment on scaffoldsZhao et al. (2013) \[[@CR52]\]Periodontal ligament stem cells (PDLSCs)400 g10 minHardware: NRCell viability and proliferation assay by MTT assayALP activityGene expression of BSP, OCN, ColI, and CP23 by RT-PCRCell viability maintainedIncreased proliferation during 7 daysReduced ALP activity at 7 daysDown-regulation of BSP and OCN expression at 7, 14 and 21 daysUp-regulation PDL-related genes ColI and CP23*Note. NR* not reported, *MTT* 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide, *ERK* extracellular signal-regulated kinase, *RANKL* receptor activator of NF-β ligand, *OPG* osteoprotegerin, *ALP* alkaline phosphatase, *SRB* sulforhodamine B, *cbfa1* core-binding factor subunit alpha-1, *LPS* lipopolysaccharide, *VEGF* vascular endothelial growth factor, *ICAM-1* intercellular adhesion molecule 1, *ELISA* enzyme-linked immunosorbent assay, *BMP* bone morphogenetic protein, *RT-PCR* reverse transcription polymerase chain reaction, *BrdDU* bromodeoxyuridine, *WST-1* water soluble tetrazolium-1, *LDH* lactate dehydrogenase, *CCK-8* cell counting kit-8, *BSP* bone sialoprotein, *DMP* dentin matrix protein, *MTS* 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), *TGFβ* transforming growth factor-β, *COL1a2* collagen type I alpha 2, *bFGF* basic fibroblast growth factor, *Runx2* runt-related transcription factor 2, *OCN* osteocalcin, *FN1* fibronectin, *ECM* extracellular matrix, *PPARγ2* peroxisome proliferator-activated receptor, *C/EBPα* CCAAT-enhancer-binding proteins^a^PC- 02, Nice, France^b^Hettich EBA20, Tuttlingen, Germany^c^Duo Centrifuge, Nice, France^d^Eppendorf Centrifuge 5702, Hamburg, Germany^e^Gyrozen 406, Daejeon, Korea^f^Medifuge centrifugation system, Santa Sofia, ItalyTable 2Included studiesStudy (year)Cell typePRF preparationMethodMain outcome induced by PRFBucur et al. (2019) \[[@CR53]\]Fibroblast cell line L929200 g14 minHardware: NRCell proliferation and migration using RCTAScratch assayNo effect on proliferation neither on migrationElgamal et al. (2019) \[[@CR47]\].Adipose mesenchymal stem cells (MSC)1500 rpm14 minHardware: NRCell proliferation by MTT assayIncreased proliferationGervois et al. (2019) \[[@CR54]\]Human dental pulp stem cells (hDPSCs), neural stem cell (NSC)400 g12 minHardware:^c^Metabolic activity assay by MTT assayCell proliferation by PI assayCell migration by transwell migration assayDecreased and increased metabolic activity, dependent on the PRF concentrationIncreased proliferation of hDPSCs but no effect on NSCIncreased migration of NSCGomez et al. (2019) \[[@CR55]\]Endothelial cells (EC)2000 rpm7 minHardware: NRCounting of the cells viewed under phase-contrast microscopeIncreased cell growthHerrera-Vizcaíno et al. (2019) \[[@CR56]\]Human dermal vascularendothelial cells (HDMECs)Human fibroblasts (HF)44 g or 710 g8 minHardware:^a^Immunostaining of endothelial cells marker CD31Immunohistochemical detection of CD31Protein levels of VEGF, PDGF-BB and TGFβ by ELISAIncreased CD31-positive cellsIncreased concentration of PDGF-BB of TGFβ at day 4 in HDMECs and HFNo effect on VEGFKargarpour et al. (2019) \[[@CR57]\]Murine primary macrophages,RAW264.7 cells1570 rpm12 minHardware:^d^Cell viability by MTT assay and live-dead stainingCell proliferation by BrdUCaspase 3 activity assayWestern blot for cleaved caspase 3Gene expression of osteoclast marker genes TRAP, Cathepsin K, DCSTAMP, NFATc1, OSCAR and pro and anti-apoptotic marker genes, caspase-3, Bax and Bcl2L1 by RT-PCRTRAP stainingPit formation assayMaintenance of cell viability and enhanced cell proliferationReduced caspase 3 activity and suppression of cleaved caspase-3Supression of osteoclastogenesisSuppression of the expression of TRAP, Cathepsin K, DCSTAMP, NFATc1, OSCARReduced number of multinucleated TRAP positive cellsReduced pit formation on dentine slicesKasnak et al. (2019) \[[@CR58]\]Human oral keratinocyte (HMK) cells2700 rpm15 minHardware:^e^Cell proliferation by CellTiter 96 assayProtein levels of IL1β, IL1Ra, IL8, MCP1, and VEGF by ELISAIncreased proliferation on titanium and hydroxyapatite discsIncreased concentration of IL1β, IL1Ra, IL8, MCP1, and VEGF on titanium and hydroxyapatite discsLi et al. (2018) \[[@CR59]\]Human periodontal ligament cells (hPDLCs)750 g 12 min + 500 g 5 minHardware: NRCell proliferation using CCK-8ALP activity assayMineralization assay by alizarin red stainingGene expression of RUNX2, Osterix and Osteocalcin by RT-PCRProtein expression of RUNX2 by Western blotIncreased proliferation at day 1, 2 and 3Increased ALP activity at 7 and 14 daysIncreased mineralization at 14 daysIncreased expression of RUNX2, Osterix at 5 and 7 days and Osteocalcin at 7 daysIncreased protein expression of RUNX2 at day 5Mahendran et al. (2019)\[[@CR60]\]Fibroblast cell line L9293000 rpm10 minHardware: NRCell viability by MTT assayMaintenance of cell viabilityMudalal et al. (2019) \[[@CR61]\]Human gingival fibroblast3000 rpm12 minHardware:^b^Gene expression of IL1β, IL6 and TNFα by RT-PCRDecreased expression of IL1β, IL6 and TNFαNasirzade et al. (2019) \[[@CR62]\]Murine primary macrophages,Raw 264.7 cells1570 rpm12 minHardware:^d^Gene expression of M1 marker genes IL1β, IL6; M2 genes Arg1, Ym1 and lipoxygenases, ALOX12, and ALOX15 by RT-PCRIL6 levels by ELISANF-휅B intracellular translocation by ImmunofluorescentDecreased expression of IL1β and IL6Increased expression of Arg1, Ym1 and lipoxygenasesIncreased IL6 protein levelReduced intracellular translocation of NF-휅BRatajczak et al. (2018) \[[@CR63]\]HUVEC400 g12 minHardware:^c^Cell proliferation by MTT assay and propidium iodide assayCell migration by transwell migration assayAngiogenic potential by Tube Formation assayIncreased proliferationEnhanced migrationIncreased tube formationSteller et al. (2019) \[[@CR64]\]Primary human osteoblasts (OB)400 g10 minHardware:^f^Viability by MTT assayCell adhesion to titanium surface by RTCA and cell wash assayMaintenance of cell viabilityNo effect on adhesion to titanium surfaceSteller et al. (2019) \[[@CR64]\]Human gingival fibroblasts (GF), human osteoblasts (hOB)400 g10 minHardware:^f^Cell viability by MTT assayCell migration by scratch assayCell viability maintained at 24 and 72 h in OB and at 72 h in GFIncreased migration of GF and OB at 24, 48 and 72 hIncreased proliferationVerboket et al. (2019)\[[@CR40]\]Bone marrow monuclear cells (BMC)60 g3 min208 g8 minHardware:^a^Metabolic activity by MTS assayGene expression of VEGFA, ICAM1, MMP2, MMP7, MMP9, TGF-β1, BCL2, BAX, ALP, COL1a1, FGF23, and OPN by RT-PCRDetermination of apoptosis using Annexin-V-stainingIncreased metabolic activity at day 14Increased expression of SPPI at day 2 and 7, TGFβ, MMP2, at day 7 and MMP9 at day 14No effect on ICAM, ALP, COL1a1, FGF23 and other genes.PRF did not induce apoptosisWang et al. (2019) \[[@CR65]\]Dermal skinfibroblast cell60 g3 minHardware: NRCell viability using live and dead stainingCell migration assayCell proliferation using CCK-8Gene expression of PDGF, TGFβ, COL1a1, andFN1 by RT-PCRImmunofluorescent staining of collagen type IMaintenance of cell viabilityIncreased the migrationIncreased proliferation at day 3 and 5Increased expression of PDGF, TGFβ, COL1a1, and FN1 at 3 and 7 days.Increased collagen type I staining*Note. NR* not reported, *MTT* 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide, *ALP* alkaline phosphatase, *COL1A1* collagen 1 alpha 1, *RT-PCR* reverse transcription polymerase chain reaction, *ELISA* enzyme-linked immunosorbent assay, *VEGF* vascular endothelial growth factor, *ICAM1* intercellular adhesion molecule, *SPPI* osteopontin, *PDGF-BB* platelet-derived growth factor, *PI* propodeum iodide, *BDNF* brain-derived neurotrophic factor, *CCK-8* cell counting kit-8, *TGFβ* transforming growth factor-β, *TRAP* tartrate-resistant acid phosphatase, *DCSTAMP* dendritic cell-specific transmembrane protein, *NFATc1* nuclear factor of activated T-cells, *OSCAR* osteoclast-associated receptor, *Bax* Bcl2-associated x protein, *Bcl2* B cell lymphoma 2, *MCP-1* monocyte chemotactic protein-1, *MTS* 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), *FGF23* basic fibroblast growth factor, *TNF-α* tumor necrosis factor, *Arg1* arginase-1, *ALOX* arachidonate lypoxigenase, *NF* nuclear factor kappa-light-chain-enhancer of activated B cells, *RTCA* real-time-cell analyzer assay, *M-CSF* macrophage colony stimulating factor, *MMP* matrix metalloproteinase, *FN1* fibronectin^a^Duo Centrifuge, Nice, France^b^Eppendorf Centrifuge 5702, Hamburg, Germany^c^Intraspin TM, Intra-Lock International, Boca Raton, FL^d^Z 306 Hermle Universal Centrifuge, Wehingen, Germany^e^SL8R, Thermo Fisher Scientific, Waltham, MA^f^Allegra X-12R-Centrifuge, Brea, California

Proliferation {#Sec13}
-------------

PRF increased proliferation of mesenchymal cells, for example from bone of different origin \[[@CR19], [@CR24]--[@CR26], [@CR28], [@CR45], [@CR50], [@CR66], \], bone marrow \[[@CR32], [@CR39]\], periosteum \[[@CR27]\], adipose tissue \[[@CR37], [@CR47], [@CR68]\], and skin \[[@CR65], [@CR48]\]. Also, fibroblasts from gingiva \[[@CR38], [@CR44]\], periodontal ligament \[[@CR18], [@CR52], [@CR59]\], papilla \[[@CR30]\], and dental pulp responded to PRF with increased proliferation \[[@CR29], [@CR31], [@CR43], [@CR54]\]. These observations were reproduced in embryonic kidney fibroblasts and in various cell lines such as HEK293, MG-63 osteosarcoma cells, human oral keratinocytes, SIRC, and 3T3 cells \[[@CR18]\]. Mesenchymal cells, endothelial cells \[[@CR23], [@CR42], [@CR55], [@CR63]\], epithelial cells \[[@CR22]\], and macrophages \[[@CR69]\] also responded to PRF with increasing proliferation. In contrast, PRF failed to induce proliferation of L929 fibroblasts \[[@CR53]\] and human mesenchymal stem cells on collagen scaffolds \[[@CR17]\]. In general, PRF maintained cell viability \[[@CR33], [@CR63]--[@CR66], \] without inducing apoptosis \[[@CR40]\]. Overall, there is a general consensus that PRF has a potent mitogenic activity.

Migration {#Sec14}
---------

There are various methods to identify the impact of PRF on cell migration including the scratch assay \[[@CR70]\] and the traditional Boyden chamber approach \[[@CR71]\]. Regardless of the method used, PRF increased the migration of neural stem cells \[[@CR54]\] along with cells of the mesenchymal lineage isolated from bone \[[@CR45], [@CR64]\], bone marrow \[[@CR72]\], gingiva \[[@CR38], [@CR64], [@CR36]\], apical papilla \[[@CR30]\], and skin \[[@CR65], [@CR48]\]. Similarly, endothelial cells responded to PRF with an increased migration \[[@CR63], [@CR72], [@CR41]\]. In contrast, an inhibitory effect of PRF on cell migration was also observed on bone marrow cells but likely due to the aggregation and proliferation effect of PRF that precedes migration \[[@CR32]\]. Likewise, in one recent study, PRF failed to induce migration on L929 fibroblasts \[[@CR53]\]. However, the general view is that PRF supports cell motility.

Alkaline phosphatase and alizarin red staining {#Sec15}
----------------------------------------------

The main early marker of osteogenic differentiation is alkaline phosphatase \[[@CR73]\]. Various studies showed that PRF increases the expression or the activity of alkaline phosphatase in cells of the mesenchymal lineage isolated from bone \[[@CR45], \], bone marrow \[[@CR25]\], apical papilla \[[@CR30]\], dental pulp \[[@CR31], [@CR34], [@CR43], [@CR49]\], periodontal ligament \[[@CR59], [@CR74]\], osteosarcoma cell lines \[[@CR21]\], and other tissues \[[@CR24]\]. Moreover, PRF increased mineralized nodules in cells from dental pulp \[[@CR34], [@CR43], [@CR49]\], calvaria bone \[[@CR28]\], bone marrow \[[@CR32]\], and periodontal ligament \[[@CR59]\]. Conversely, one study showed an inhibitory effect of PRF on alkaline phosphatase activity \[[@CR52]\]. In two other reports, PRF failed to change alkaline phosphatase activity and did not change alkaline phosphatase expression in rat calvaria osteoblasts \[[@CR28]\] and bone marrow cells \[[@CR40]\], respectively. Taken together, all but three studies reported an increase of alkaline phosphatase in response to PRF exposure.

Growth factors and extracellular matrix {#Sec16}
---------------------------------------

PRF caused a moderate expression of various growth factors in mesenchymal and endothelial cells such as TGFβ \[[@CR38], [@CR46], [@CR52], [@CR56], [@CR65], [@CR36]\], PDGF \[[@CR23], [@CR38], [@CR40], [@CR46], [@CR52], [@CR56], [@CR65], [@CR36]\], and VEGF \[[@CR23], [@CR37], [@CR58]\]. Dental pulp cells treated with PRF increased expression of dentin sialoprotein and dentin matrix protein 1 \[[@CR29], [@CR34], [@CR49]\]. With respect to changes in the expression of extracellular matrix protein, PRF increased collagen type 1 in mesenchymal cells of the bone \[[@CR45]\], skin \[[@CR65]\], and gingiva \[[@CR38], [@CR73]\]. Likewise, PRF increased the expression of osteopontin, MMP2, and MMP9 in human bone marrow cells \[[@CR40]\]. Conversely, PRF reduced the expression of bone sialoprotein and osteocalcin along with a transient downregulation of collagen type 1 in periodontal ligament cells \[[@CR52]\]. Similarly, a downregulation of bone sialoprotein, dentin matrix protein 1, and dentin sialoprotein in cells from the papilla was reported \[[@CR30]\]. It should be noted, however, that this downregulation disappeared after 14 days of stimulation \[[@CR30]\]. In general, the reported increase of gene expression by PRF is moderate.

Cell adhesion {#Sec17}
-------------

Cell adhesion proteins were enhanced by PRF, for example, ICAM-1 and E-selectin in cocultures of osteogenic and endothelial cells \[[@CR23]\] and ICAM-1 in pulp cells \[[@CR34]\]. Furthermore, PRF supported adhesion of mesenchymal cells \[[@CR17]\], HUVEC \[[@CR41]\], U2OS \[[@CR50]\], and HBASC \[[@CR51]\] on different scaffolds. These positive results nonetheless were not replicated on titanium surfaces \[[@CR46]\] and culture plates \[[@CR45]\]. Together, these observations suggest that in the majority of experiments, PRF could support cell adhesion.

Cell signaling, inflammation, and osteoclastogenesis {#Sec18}
----------------------------------------------------

PRF enhanced the phosphorylation of Akt, heat shock protein 47 and lysis oxidase in osteosarcoma cells \[[@CR50]\], and VEGFR2 in endothelial cells \[[@CR35]\]. PRF enhanced phosphorylation of ERK in osteosarcoma cells \[[@CR19]\], and periodontal fibroblasts \[[@CR74]\] along with an increase in OPG expression in both cell types. This PRF-induced OPG expression was also reported on dental pulp cells \[[@CR31]\]. Moreover, PRF reduced LPS-induced cytokine production in pulp cells and enhanced the up-regulation of odontoblastic differentiation markers DSP and DMP-1 in these cells \[[@CR34]\]. Similarly, PRF suppressed the LPS- and saliva-induced pro-inflammatory cytokines on primary and RAW264.7 macrophages and attenuated the translocation of NF-κB into the nucleus \[[@CR69]\]. This anti-inflammatory effect was replicated in gingival fibroblasts \[[@CR61]\]. In addition, in dental pulp cells, PRF increased DSP and DMP1 expression along with an activation of BMP 2/4 signaling and phosphorylation of SMAD1/5/8 cascade \[[@CR49]\]. Osteoclasts originate from hematopoietic progenitors and in the presence of the survival factor (M-CSF) and RANKL differentiate into osteoclasts staining positive for TRAP. PRF suppressed the expression of osteoclast marker genes TRAP, DCSTAMP, NFATc, and OSCAR. Altogether, these results suggest that PRF can affect central signaling pathways, possesses an anti-inflammatory effect, and is capable of inhibiting osteoclastogenesis \[[@CR57]\].

Discussion {#Sec19}
==========

This systematic review encompassed in vitro studies using PRF and can be viewed as an extension of the previous work of Miron et al. \[[@CR16]\]. Our aim was to gather the current in vitro evidence on cellular responses to PRF. Despite the steadily increasing number of in vitro studies, much of the available evidence has focused on confirming similar findings. The majority of studies assessed the impact of PRF on proliferation, adhesion, migration, and differentiation mainly on mesenchymal cells and to some extent, endothelial and epithelial cells. Overall, PRF triggered an increase in the above-mentioned parameters and revealed anti-inflammatory properties. PRF also showed a moderate but consistent capacity to modulate the expression of target genes activating different signaling pathways.

A meta-analysis could not be performed as the included studies revealed heterogeneity in terms of study design, evaluation methods, outcome measures, and observation periods. Besides the original L-PRF protocol, other PRF protocols were used, however, most studies did not provide enough details. These details are of importance as with different protocols \[[@CR3]\], i.e., centrifugation time and g-force, characteristics such as the release of growth factors or the content of living cells are substantially changed \[[@CR75]\]. For instance, by reducing the g-force, there is an improvement in growth release and cell content. This finding is considered one of the major innovations in PRF leading to the development of new protocols including advanced platelet-rich fibrin (A-PRF+), injectable PRF (i-PRF), and liquid PRF (fluid-PRF). In addition, there are other factors that were not considered in the different preparation protocols such as the centrifugation tubes which have a strong impact on the clot size \[[@CR76]\]. Indeed, the silica used to coat plastic tubes might contaminate PRF and thereby provoking inflammation \[[@CR77]\]. Likewise, differences in g-forces, blood volume, hematocrit levels, centrifugation time, and handling of PRF membranes impede an accurate comparison between the protocols. Furthermore, PRF lysates, PRF conditioned medium, and PRF exudates should also be distinguished from traditional protocols. Although these issues are at the heart of scientific discussion \[[@CR78], [@CR79]\], the main in vitro findings are rather consistent.

Successful tissue regeneration and osseointegration rely on the response of the surrounding cells. These biological processes inevitably require proliferation, migration, and differentiation of cells at the treatment site.

PRF consistently increased cell proliferation irrespective of the cell type and PRF preparation. One interesting setting was the increased cell proliferation on collagen matrices \[[@CR72]\] and titanium surfaces \[[@CR46]\] upon PRF coating. It is worth noting that two studies found a conspicuously reduced proliferation in gingival fibroblast \[[@CR44]\] and dental pulp stem cells \[[@CR43]\]. It is difficult, however, to determine why PRF led to a decline in cell proliferation. PRF membranes covering cells might decrease oxygenation \[[@CR44]\]. Nonetheless, PRF preparation without providing enough details complicates the interpretation of the data \[[@CR43]\]. Despite these shortcomings, the majority of the in vitro studies suggest a mitogenic activity of PRF for various cell types that might be attributed to the strong mitogen PDGF released by activated platelets \[[@CR13], [@CR80]\].

Cell migration was positively induced in all but two of the selected studies. This chemotactic effect is likely due to the presence of growth factors contained in platelets such as PDGF \[[@CR12]\]. This growth factor, for example, pushes proliferation of osteogenic cells in vitro \[[@CR81]\]. In addition, endothelial cells followed a similar pattern of displaying an increase in migration upon exposure to PRF \[[@CR40]\]. Although the activation of platelets might account for these observations \[[@CR11]\], the precise mechanism remains to be elucidated. In support of the mitogenic and chemotactic activity, PRF enhanced the phosphorylation of Akt \[[@CR50]\], and ERK \[[@CR19], [@CR74]\] similar to what is observed in isolated platelets \[[@CR12]\]. Conversely, inhibition of migration by PRF has been reported in alveolar bone marrow cells \[[@CR32]\]. This effect might be explained by the aggregation and proliferation effect of PRF that precedes migration and also by methodological differences, which precludes an interpretation and a comparison with the other studies \[[@CR3]\]. Despite these inconsistencies, PRF is able to induce cell migration, likely due to the presence of growth factors such as PDGF with chemotactic activity.

Cell differentiation is commonly assessed by means of measuring alkaline phosphatase and alizarin red staining. Various studies showed that PRF increases the expression or the activity of alkaline phosphatase in cells of the mesenchymal lineage \[[@CR24], [@CR25], [@CR29]--[@CR31], [@CR34], [@CR43], [@CR45], [@CR49], [@CR65], [@CR59], [@CR74]\]. Some data, nonetheless, are conflicting since PRF can also reduce alkaline phosphatase activity \[[@CR52]\] consistent with the effects of supernatants of isolated platelets \[[@CR12]\]. This reduction may be attributed to TGF-β \[[@CR82]\] and PDGF \[[@CR12]\]. On the other hand, the increased mineralized nodules elicited by PRF in cells from dental pulp \[[@CR34], [@CR43], [@CR49]\], calvaria bone \[[@CR28]\], bone marrow \[[@CR32]\], and periodontal ligament \[[@CR59]\] appear to be a consequence of the enhanced proliferation, alkaline phosphatase activity, and production of collagen matrix. These in vitro findings, however, have to be interpreted with caution as proliferation and differentiation do not occur simultaneously \[[@CR73]\].

With respect to growth factors such as TGFβ, PDGF, and VEGF, PRF moderately increased their expression. Regarding extracellular matrix proteins, PRF moderately increased the expression of collagen type 1, which is a known TGFβ target gene \[[@CR83], [@CR84]\] in mesenchymal cells of various origins. In line with collagen type 1 synthesis, PRF activates the expression of HSP47 and lysine oxidase \[[@CR50]\]. Cell adhesion proteins were enhanced by PRF \[[@CR23]\], however, they are not necessarily responsible for the increased cell adhesion on different scaffolds \[[@CR51]\]. Together, these observations suggest that PRF induces moderate changes in gene expression. In contrast, recent data at our lab indicate a robust activation of TGFβ target genes IL11, PRG4, and NOX4 by PRF lysates (Di Summa et al. unpublished observation). TGF-β couples osteogenesis with angiogenesis by providing a pro-osteogenic microenvironment in vivo \[[@CR62]\]. As TGF-β induces pro-osteogenic factors and TGF-β type 1 receptor inhibitor rescues uncoupled bone remodeling in vivo \[[@CR62]\], PRF-derived TGF-β may support bone regeneration.

This systematic review revealed an anti-inflammatory effect of PRF. Moreover, during the submission process of the present review, new studies were published highlighting these anti-inflammatory effects of PRF. For example, PRF reduced the LPS-induced proinflammatory cytokine release in gingival fibroblasts \[[@CR61]\]. In addition, we have recently shown that PRF reduces the expression of the M1 marker genes interleukin 1β (IL1β) and interleukin 6 (IL6) in bone marrow macrophages \[[@CR69]\]. This anti-inflammatory effect might be explained by the high amounts of TGFβ in PRF \[[@CR73]\] capable of modulating the M1 and M2 polarization along with the generation of pro-resolving lipid mediators \[[@CR69]\]. Additionally, PRF induces the expression of the M2 markers arginase-1 and chitinase-like 3 (Chil3 or YM1) thereby assisting a M1-to-M2 transition \[[@CR69]\]. Since dental implants activate the immune system during the early stages of osseointegration \[[@CR85]\], the addition of PRF may support a M2 polarization reducing the time lag for osseointegration and bone regeneration. Notably, PRF can also decrease the formation of osteoclast-like cell in a murine bone marrow culture \[[@CR57]\]. Similar findings were also reported in peripheral blood mononuclear cells derived CD14^+^ cells \[[@CR86]\]. These observations are of particular interest since the favorable effects of PRF in alveolar ridge preservation \[[@CR6]\] might be partly explained by an inhibition of osteoclastogenesis. Thus, accumulating evidence suggest that PRF possesses an anti-inflammatory activity and is capable of suppressing osteoclastogenesis.

PRF is a potent inducer of the in vitro angiogenic process indicated by endothelial proliferation, migration, and tube formation. PRF supports microvessel-like structures \[[@CR23], [@CR56]\] and induces blood vessel formation in the chorioallantoic membrane assay \[[@CR63]\]. Apart from in vitro angiogenesis, a recent report described an antimicrobial effect of PRF. In that study, both PRF membranes and PRF exudates had an antimicrobial effect against *P. gingivalis*, a key periodontal pathogen \[[@CR87]\]. Those findings support the rationale of using PRF as an adjunctive therapy for peri-implantitis \[[@CR88]\]. These observations are also in line with previous data on purified activated platelet showing an angiogenic \[[@CR11]\] and antimicrobial effect \[[@CR89]\]. Overall, these findings imply that PRF possesses angiogenic and antimicrobial properties.

We recognize that the present report has a number of limitations. PRF is widely used in regenerative dentistry, however, in vitro models represent only a narrow aspect of wound healing and bone regeneration neglecting the holistic nature of an in vivo model. Furthermore, and considering that wound healing and bone regeneration involve granulocytes, lymphocytes and other cell types, today's PRF research only covers a restricted spectrum of cells. It should also be noted that the same stimuli may play different roles depending on the differentiation stage of the target cell. For example, our group demonstrated that PRF membranes inhibit the formation of osteoclasts in bone marrow cultures \[[@CR57]\]. This inhibition, however, did not occur when osteoclastogenesis had already started \[[@CR57]\].

Future studies should, for example, include research on the immigration and activation of granulocytes and how PRF might control the resolution of inflammation. Moreover, and considering the importance of centrifugation tubes and the possible impact of silica coating, more studies investigating this issue are needed for the optimization of PRF. Finally, the overall question of whether the in vitro PRF research reflects the clinical reality serving as a surrogate parameter to adapt the current PRF protocols remains to be clarified.

Conclusion {#Sec20}
==========

Despite some notable differences of the included studies, the overall findings suggest a benefit of PRF on cell proliferation, migration, adhesion, differentiation, and inflammation pointing towards a therapeutic potential in wound healing and regeneration.
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